Search

Search Results

• 

  Increased plasma lipocalin-2 levels correlate with disease severity and may be a marker of acute inflammatory response in patients with psoriasis

  Chuyen Thi Hong Nguyen, Oanh Phan Tram Nguyen

  21-11-2022

  https://doi.org/10.4081/dr.2022.9469

  1364

  PDF: 573

  HTML: 47

• Prevalence and association of renal disorders in Saudi adult patients with psoriasis and psoriatic arthritis: a tertiary-center retrospective cross-sectional study

  Mishari T. Alrubaiaan, Abdullah D. Alhobabi, Raghad M. Alharthi, Saad A. Alsulaiman, Abdullah N. Altasan, Ibrahim M. Momen, Mohammad Almohideb

  02-01-2025

  https://doi.org/10.4081/dr.2025.10083

  859

  PDF: 408

  HTML: 35

• Treatment satisfaction among patients with psoriasis in Saudi Arabia

  Mahdi Aldhafiri, Rahaf Almutairi, Reem Albejais, Asma Almubark, Hussain Alwesaibie, Mohammed Albesher, Manayer Almustihi

  15-04-2024

  https://doi.org/10.4081/dr.2024.9967

  1131

  PDF: 647

  HTML: 51
• 

  Erythrodermic psoriasis improved by tildrakizumab

  Giampaolo Trevisan, Lerica Germi, Luigi Naldi

  23-11-2022

  https://doi.org/10.4081/dr.2022.9448

  1365

  PDF: 642

  HTML: 28
• 

  Erythrodermic psoriasis treated with apremilast

  John Arcilla, Daniel Joe, Johnathan Kim, Yohanan Kim, VuAnh N. Truong, Navin Jaipaul

  19-09-2016

  https://doi.org/10.4081/dr.2016.6599

  2218

  PDF: 992

  HTML: 613

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  576

  PDF: 394

  HTML: 15

• Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

  Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo

  30-05-2025

  https://doi.org/10.4081/dr.2025.10414

  890

  PDF: 471

  HTML: 54

• Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

  Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

  13-09-2023

  https://doi.org/10.4081/dr.2023.9839

  2858

  PDF: 1015

  HTML: 39
• 

  Mucocutaneous presentations of consultant critical and non-critical cases of admitted COVID-19 patients, outpatients, and vaccine-associated dermatoses: a clinical atlas and a large original study of two general COVID-19 centers from Iran

  Afsaneh Sadeghzadeh-Bazargan, Azadeh Goodarzi

  23-05-2023

  https://doi.org/10.4081/dr.2023.9473

  1036

  PDF: 501

  SUPPLEMENTARY FILE: 169

  HTML: 26

• Psoriasiform eruption induced by dupilumab successfully treated with upadacitinib

  Mattia Minghini, Natale Schettini, Lucrezia Pacetti, Chiara Bocchi, Alessandro Borghi

  16-10-2025

  https://doi.org/10.4081/dr.2025.10588

  424

  PDF: 217

  HTML: 3

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  514

  PDF: 327

  HTML: 25

• Bullous pemphigoid with secondary acquired reactive perforating collagenosis: a challenging clinical case report

  Valentina Ruffo di Calabria, Elena Biancamaria Mariotti, Alberto Corrà, Alice Verdelli, Lavinia Quintarelli, Cristina Aimo, Giovanni Di Zenzo, Vincenza Maio, Daniela Massi, Marzia Caproni

  03-10-2024

  https://doi.org/10.4081/dr.2024.10087

  1130

  PDF: 627

  HTML: 101

• Pityriasis following COVID-19 vaccinations: a systematic review

  Laura Duzett, Guadalupe Mercado, Vasiliki Tasouli-Drakou, Alicia Kane, Alison Tam

  09-08-2023

  https://doi.org/10.4081/dr.2023.9742

  1392

  PDF: 780

  Supplementary Material: 162

  HTML: 86